Long time EastEnders fans will remember Kara Tointon as Dawn Swann, the archetypal ‘tart with a heart’, who faced an ...

In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...

What Is Akeega, and Why Does It Matter? Akeega is a dual-action tablet combining two medicines — niraparib and abiraterone acetate — that has been approved by the FDA in combination with prednisone (a ...

"There remains an urgent need for novel therapies for patients with BRCA2-mutated mCSPC, who face significantly faster disease progression and often shorter survival compared to those without the ...

FDA approved niraparib, abiraterone acetate, and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer, showing significant rPFS improvement in the AMPLITUDE trial. The ...

Researchers found that losing a second protein, FIGNL1, allows cancer cells missing BRCA2 to restore DNA repair by reloading RAD51 onto broken DNA strands. Normally, BRCA2 helps place RAD51 at DNA ...

One of the biggest challenges in cancer treatment is chemoresistance: tumors that initially respond well to chemotherapy become resistant over time. When that happens, treatment options are often ...

Andrew Kessel was a breaking news writer for Investopedia until October 2025. He previously covered markets for Proactive Investors, with a focus on small-cap stocks in fintech, healthcare, mining, ...

The study showed that oxidative stress, which is considered to contribute to cancer development, actually suppressed cancer in rats with BRCA2 gene mutations. Oxidative stress is considered to ...

BRCA genes, including BRCA1 and BRCA2, are tumor suppressor genes that play a crucial role in the HRR pathway for double-strand DNA breaks. Mutations in these genes lead to the loss of function of ...

Astrology has been around for more than 2,000 years, so pretty much everyone knows at least their Sun sign (what you usually respond with when someone asks, "What's your sign?"). But recently, ...

As the transaction shows, this will be the end of Chart as it is currently composed. The merger with Flowserve will create a new entity going forward. At some point, this likely should have been ...